Targets › SERPINC1
20 programs from 15 companies in 24 trials: 12 Phase 4, 6 Phase 3, 5 Phase 2, 1 Phase 1; Oncology, Cardiovascular, Other; next expected readout Dec 2026.
Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin, matriptase-3/TMPRSS7, as well as factors IXa, Xa and XIa. (UniProt, P01008)
Open in Phaseline: the race on SERPINC1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Tzu-Fei Wang | Dalteparin Sodium Antithrombin-III activator | SERPINC1 | Phase 4 | Cancer-associated Thrombosis | Dec 2026 |
| Tzu-Fei Wang | Enoxaparin Sodium Antithrombin-III activator | SERPINC1 | Phase 4 | Cancer-associated Thrombosis | Dec 2026 |
| Tzu-Fei Wang | Tinzaparin Sodium Antithrombin-III activator | SERPINC1 | Phase 4 | Cancer-associated Thrombosis | Dec 2026 |
| University of California, Irvine | Enoxaparin Sodium Antithrombin-III activator | SERPINC1 | Phase 4 | Pregnancy, High Risk | Dec 2026 |
| PAEC General Hospital, Islamabad | Enoxaparin Sodium Antithrombin-III activator | SERPINC1 | Phase 4 | Oligohydramnios | Jan 2027 |
| Medical University of Vienna | Enoxaparin Sodium Antithrombin-III activator | SERPINC1 | Phase 4 | Respiratory Insufficiency | Jan 2027 |
| Helsinki University Central Hospital | Dalteparin Sodium Antithrombin-III activator | SERPINC1 | Phase 4 | Pancreas Cancer; Liver Cancer | Feb 2027 |
| Helsinki University Central Hospital | Enoxaparin Sodium Antithrombin-III activator | SERPINC1 | Phase 4 | Pancreas Cancer; Liver Cancer | Feb 2027 |
| Helsinki University Central Hospital | Tinzaparin Sodium Antithrombin-III activator | SERPINC1 | Phase 4 | Pancreas Cancer; Liver Cancer | Feb 2027 |
| Octapharma | Human plasma derived antithrombin (Atenativ) Antithrombin (plasma-derived) | SERPINC1 | Phase 3 | Congenital Antithrombin Deficiency; Acquired Antithrombin Deficiency | Dec 2026 |
| Sunnybrook Health Sciences Centre | Dalteparin Sodium Antithrombin-III activator | SERPINC1 | Phase 3 | Traumatic Brain Injury | Dec 2026 |
| Queen Mary University of London | Enoxaparin Sodium Antithrombin-III activator | SERPINC1 | Phase 3 | Thrombosis | Aug 2028 |
| Queen Mary University of London | Tinzaparin Sodium Antithrombin-III activator | SERPINC1 | Phase 3 | Thrombosis | Aug 2028 |
| Sanofi | Fitusiran Antithrombin mRNA RNAi inhibitor | SERPINC1 | Phase 3 | Hemophilia | – |
| Endeavor Health | Enoxaparin Sodium Antithrombin-III activator | SERPINC1 | Phase 2 | Adverse Pregnancy Outcome | Mar 2027 |
| Yale University | Enoxaparin Sodium Antithrombin-III activator | SERPINC1 | Phase 2 | Deep Venous Thrombosis | Apr 2027 |
| University Hospital, Linkoeping | Tinzaparin Sodium Antithrombin-III activator | SERPINC1 | Phase 2 | Epithelial Ovarian Cancer | Dec 2027 |
| Instituto Grifols | AT-III concentrate (ATIII-DAF/DI) Antithrombin III (plasma-derived concentrate) | SERPINC1 | Phase 2 | Antithrombin III Deficiency | – |
| European Foundation for Study of Chronic Liver Failure | Enoxaparin Sodium Antithrombin-III activator | SERPINC1 | Phase 2 | Liver Cirrhosis | – |
| Cairo University | Enoxaparin Sodium Antithrombin-III activator | SERPINC1 | Phase 1 | Deep Venous Thrombosis | – |
Pancreas Cancer (3) Liver Cancer (3) Cancer-associated Thrombosis (3) Thrombosis (2) Deep Venous Thrombosis (2) Adverse Pregnancy Outcome (1) Pregnancy, High Risk (1) Liver Cirrhosis (1) Epithelial Ovarian Cancer (1) Respiratory Insufficiency (1) Traumatic Brain Injury (1) Congenital Antithrombin Deficiency (1)
small molecule (15), protein or peptide (3), mixed (1), other (1)
Helsinki University Central Hospital (3) Tzu-Fei Wang (3) Queen Mary University of London (2) Endeavor Health (1) University of California, Irvine (1) Yale University (1) European Foundation for Study of Chronic Liver Failure (1) Cairo University (1) University Hospital, Linkoeping (1) Medical University of Vienna (1) Sunnybrook Health Sciences Centre (1) Octapharma (1) PAEC General Hospital, Islamabad (1) Instituto Grifols (1) Sanofi (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.